​

4D Molecular Therapeutics Ownership | Who Owns 4D Molecular Therapeutics?

OverviewForecastRevenueFinancialsChart

4D Molecular Therapeutics Ownership Summary

4D Molecular Therapeutics is owned by 72.22% institutional investors, 3.85% insiders, and 23.93% retail investors. Blackrock is the largest institutional shareholder, holding 9.94% of FDMT shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 3.32% of its assets in 4D Molecular Therapeutics shares.

FDMT Ownership Benchmark

TypeName% Inst% Insiders% Retail
Stock4D Molecular Therapeutics72.22%3.85%23.93%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock4.90M9.94%$102.79M
Bvf inc/il4.63M8.28%$17.17M
Ra capital management4.56M8.16%$16.93M
Goldman sachs group4.27M7.70%$23.81M
Blackrock funding, inc. /de4.01M7.17%$14.88M
Vanguard group2.86M5.15%$15.93M
Janus henderson group2.25M4.05%$12.54M
Novo2.00M3.58%$7.42M
Morgan stanley1.46M2.96%$30.65M
Millennium management1.42M2.56%$7.91M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il4.63M0.61%$17.17M
Novo2.00M0.52%$7.42M
Ra capital management4.56M0.29%$16.93M
Decheng capital239.51K0.22%$888.58K
Privium fund management b.v.121.00K0.15%$673.97K
Velan capital investment management lp10.00K0.05%$55.70K
Redmile group112.17K0.04%$416.14K
Peloton wealth strategists25.00K0.04%$93.00K
Arrowmark colorado514.61K0.03%$1.91M
Kera capital partners24.07K0.03%$209.15K

Top Buyers

HolderShares% AssetsChange
Millennium management1.42M0.00%1.34M
Goldman sachs group4.27M0.00%683.94K
Blackrock4.90M0.00%612.35K
Jpmorgan chase820.07K0.00%504.09K
Norges bank500.82K0.00%500.82K

Top Sellers

HolderShares% AssetsChange
Viking global investors lp---2.93M
Braidwell lp---1.23M
Casdin capital---1.15M
State street1.11M0.00%-1.00M
Redmile group112.17K0.04%-885.07K

New Positions

HolderShares% AssetsChangeValue
Norges bank500.82K0.00%500.82K$2.79M
Hudson bay capital management lp113.30K0.01%113.30K$2.38M
Bnp paribas arbitrage, snc95.42K0.00%95.42K$531.51K
Simplex trading14.73K-14.73K$82.00K
Quadrature capital11.26K0.00%11.26K$41.76K

Sold Out

HolderChange
Northwestern mutual wealth management-1.00
Innealta capital-4.00
Nelson, van denburg & campbell wealth management group-8.00
Allspring global investments-27.00
Rothschild investment-35.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025120-4.00%40,390,122-6.26%721.21%5823.40%39-35.00%
Mar 31, 2025125-14.38%43,088,441-8.05%771.09%47-43.37%6036.36%
Dec 31, 20241442.86%46,861,479-18.79%840.78%829.33%442.33%
Sep 30, 2024140-4.11%57,700,8380.63%1030.77%76-7.32%4210.53%
Jun 30, 2024146-6.41%57,338,9551.87%1160.89%82-21.15%382.70%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF1.54M3.32%-
Vanguard Total Stock Mkt Idx Inv1.50M3.22%-33.14K
Federated Hermes MDT Small Cap Core IS1.12M2.42%253.62K
Federated Hermes MDT SCC Institutional1.12M2.42%253.62K
iShares Russell 2000 ETF1.00M2.14%-
SPDR® S&P Biotech ETF986.40K2.13%14.03K
Janus Henderson Global Life Sciences835.18K1.80%-116.90K
Janus Henderson Global Life Sciences D835.18K1.79%-3.02K
Janus Global Life Science AUSD717.92K1.55%-20.50K
Janus Henderson Glb Life Scn I2 USD711.63K1.52%-4.41K

Recent Insider Transactions

DateNameRoleActivityValue
Oct 24, 2025Bizily Scott Chief Legal OfficerSell$32.14K
Oct 16, 2025Bizily Scott Chief Legal OfficerSell$16.63K
Oct 09, 2025Bizily Scott Chief Legal OfficerSell$24.08K
Sep 23, 2025Bizily Scott Chief Legal OfficerSell$19.26K
Sep 16, 2024Bizily Scott Chief Legal OfficerSell$8.16K

Insider Transactions Trends

DateBuySell
2024 Q4--
2024 Q3-6
2024 Q2-6
2024 Q1-13
2023 Q4-2

FDMT Ownership FAQ

Who Owns 4D Molecular Therapeutics?

4D Molecular Therapeutics shareholders are primarily institutional investors at 72.22%, followed by 3.85% insiders and 23.93% retail investors. The average institutional ownership in 4D Molecular Therapeutics's industry, Biotech Stocks , is 307.10%, which 4D Molecular Therapeutics falls below.

Who owns the most shares of 4D Molecular Therapeutics?

4D Molecular Therapeutics’s largest shareholders are Blackrock (4.9M shares, 9.94%), Bvf inc/il (4.63M shares, 8.28%), and Ra capital management (4.56M shares, 8.16%). Together, they hold 26.38% of 4D Molecular Therapeutics’s total shares outstanding.

Does Blackrock own 4D Molecular Therapeutics?

Yes, BlackRock owns 9.94% of 4D Molecular Therapeutics, totaling 4.9M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 102.79M$. In the last quarter, BlackRock increased its holdings by 612.35K shares, a 14.29% change.

Who is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is 4D Molecular Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.61% of its assets in 4.63M 4D Molecular Therapeutics shares, valued at 17.17M$.

Who is the top mutual fund holder of 4D Molecular Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of 4D Molecular Therapeutics shares, with 3.32% of its total shares outstanding invested in 1.54M 4D Molecular Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools